Visitors Now:
Total Visits:
Total Stories:
Profile image
By Global Market Insights Inc.
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

US Multiple Sclerosis Therapeutics Drugs Industry Forecast to 2024

Tuesday, October 4, 2016 0:26
% of readers think this story is Fact. Add your two cents.

(Before It's News) adds “Multiple Sclerosis -US Drug Forecast and Market Analysis to 2024” new report to its research database. The report spread across 233 pages with table and figures in it.

Multiple Sclerosis (MS) is an inflammatory autoimmune disease of the central nervous system which leads to neurological disability. The exact underlying cause of the disease is poorly understood; however, it appears to involve a complex combination of genetic susceptibility and a non-genetic trigger. The MS therapeutics market has entered an exciting phase, with an upsurge of available treatment options. Over the forecast period, patients are expected to continue to switch to the oral disease-modifying therapies (DMTs), lessening the stronghold of the established injectable treatments. There are also several promising products in the late-stage pipeline, with a diverse range of mechanisms offering clinical advantages intended to address unmet needs. Both pipeline and marketed DMTs are seeking approval for the treatment of progressive MS, which currently represents a significant unmet need. These factors are expected to increase treatment rates throughout the 10MM resulting, driving market growth. However, this will be largely offset by brand erosion due to the emergence of biosimilars and generic small molecules.

Browse full table of contents and data tables at

The Report estimates that drug sales for MS in the US reached $11.9 billion during 2014, making this the largest market within the 10MM. Slow growth is expected to occur between 2014 and 2018, attributed to the continued uptake of products with high ACOTs. This will be followed by a two-year decline due to the generic erosion of key brands, namely Teva’s Copaxone and Novartis’ Gilenya. However, growth will return from 2020 onwards as generic erosion is offset by sales of novel pipeline agents.


-Overview of MS including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
-Detailed information on the key drugs in the US including product MScription, safety and efficacy profiles as well as a SWOT analysis.
-Sales forecast for the top drugs in the US from 2014-2024.
-Analysis of the impact of key events as well the drivers and restraints affecting the US MS market.

Request a sample copy at  

Reasons to buy

-Understand and capitalize by identifying products that are most likely to ensure a robust return
-Stay ahead of the competition by understanding the changing competitive landscape for MS.
-Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
-Make more informed business decisions from insightful and in-depth analysis of drug performance
-Obtain sales forecast for drugs from 2014-2024 in the US.

Enquiry before Buying at   

To receive personalized assistance write to us @ with the report title in the subject line along with your questions or call us at +1 866-764-2150

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.